纳洛酮治疗急性重症脑梗死的多中心随机对照研究

A multi-center controlled randomized clinical trial using nalxone in the treatment of acute cerebral infarction with conscious disturbance

目的评价阿片受体阻滞剂———纳洛酮治疗重症脑梗死的有效性和安全性。方法将60例格拉斯哥昏迷评分(GCS)为6～12分的前循环重症脑梗死患者随机分为常规组(n=28)和纳洛酮组(n=32),观察其对GCS和神经缺失功能的改善及其安全性。结果纳洛酮组GCS逐步上升,7d后显著高于常规组,21d的神经功能评分也比常规组佳,研究期间未见明显与治疗有关的不良反应。结论纳洛酮对重症脑梗死有较好的促醒和改善神经功能的作用,8mg·d-1的用量是安全的。

AIM To assess the clinical effects of naloxone in treatment of acute cerebral infarction with coma. METHODS Sixty patients (GSC 6-12) were randomly divided into two groups(32 patients were treated with naloxone and 28 patients were treated on routine). The improvement of neural dysfunction and coma were observed, and adverse drug reactions(ADRs) were monitored. RESULTS A gradual increase was revealed in the treatment group's GCS, especially after 7 d. Neural dysfunction also reduced in 21 d. There were no severe ADRs related to naloxone in this study. CONCLUSION Intravenous naloxone(8 mg·d -1) is efficient and safe in the treatment of cerebral infarction with coma.